Selected article for: "CoV infection and International license"
Author: Ping Xu; Guo-Dong Sun; Zhi-Zhong Li
Title: Clinical Characteristics of Two Human to Human Transmitted Coronaviruses: Corona Virus Disease 2019 versus Middle East Respiratory Syndrome Coronavirus.
  • Document date: 2020_3_10
    • ID: 2u6ki9dv_38
    Snippet: Up to now, no effective strategy has been found for treatment of COVID-19 infection [50] . Currently, the measure to COVID-19 is to control the source of the infection; taking personal protective works to reduce the risk of transmission; and early diagnosing, isolating and supportive treating for confirmed patients. In the present study, our systematic results of cure rate of drug for MERS-COV infection indicated that ribavirin and interferon, os.....
    Document: Up to now, no effective strategy has been found for treatment of COVID-19 infection [50] . Currently, the measure to COVID-19 is to control the source of the infection; taking personal protective works to reduce the risk of transmission; and early diagnosing, isolating and supportive treating for confirmed patients. In the present study, our systematic results of cure rate of drug for MERS-COV infection indicated that ribavirin and interferon, oseltamivir, antivirals and intravenous immunoglobulin all had been effective for MERS-COV infection, with the cure rate of those drugs was 74.2%, 69.2%, 67.1% and 62.5% respectively. Thus, we . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • cc NC ND International license and effective strategy: 1, 2
    • cc NC ND International license and infection source: 1, 2, 3
    • cc NC ND International license and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cc NC ND International license and intravenous immunoglobulin: 1
    • cc NC ND International license and MERS COV infection: 1
    • cc NC ND International license and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • cc NC ND International license and systematic result: 1
    • confirm patient and present study: 1, 2
    • cure rate and drug cure rate: 1, 2, 3
    • cure rate and effective strategy: 1, 2, 3, 4, 5
    • cure rate and MERS COV infection: 1
    • cure rate and present study: 1, 2, 3, 4
    • early diagnosing and International license: 1
    • early diagnosing and MERS COV infection: 1, 2
    • early diagnosing and present study: 1, 2
    • effective strategy and International license: 1, 2, 3, 4
    • effective strategy and intravenous immunoglobulin: 1
    • effective strategy and MERS COV infection: 1, 2, 3, 4, 5
    • effective strategy and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25